Sanofi (EPA:SAN) Stock Price Passes Below Two Hundred Day Moving Average – What’s Next?

Shares of Sanofi (EPA:SAN) crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of €83.82 and traded as low as €81.26. Sanofi shares last traded at €82.29, with a volume of 1,323,958 shares traded.

Key Sanofi News

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi struck a large discovery collaboration with Earendil Labs (reported as ~$2.5–2.56bn) to discover bispecific antibodies for autoimmune diseases — a sizable deal that could add long‑term pipeline value and milestones/royalties. Earendil Labs and Sanofi Form $2.5 Billion Collaboration to Discover Antibodies for Autoimmune Diseases
• Positive Sentiment: BrightInsight’s patient app, developed with Sanofi, reportedly improved treatment adherence and persistence — a commercialization/real‑world evidence positive that can support product performance and payer conversations. BrightInsight’s Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence
• Positive Sentiment: Analysts/publications continue to flag Sanofi as undervalued relative to peers, citing strong vaccine and specialty-care cash flows — supportive narrative for investors looking for valuation upside. Best Undervalued Stocks 2026: CleanSpark, Uber, Sanofi Analysis
• Neutral Sentiment: Sanofi’s PERSEUS late‑stage PPMS trial for tolebrutinib is approaching a key inflection/readout point — a potential catalyst but outcome and regulatory interpretation remain uncertain until data are published. Sanofi’s PERSEUS PPMS Trial Nears Key Inflection Point for Tolebrutinib and MS Market
• Negative Sentiment: The FDA rejected tolebrutinib, citing liver‑injury risk and an unclear benefit-risk profile — a major near-term regulatory setback that undermines expected sales, could remove a late-stage asset, and raises questions about development strategy. FDA Flags Liver Injury Risk In Sanofi’s Rejected Multiple Sclerosis Drug
• Negative Sentiment: Coverage of the FDA rejection emphasizes severe liver‑injury concerns and unclear benefit, repeating themes across outlets — this increases downside risk to Sanofi’s MS franchise forecasts and could pressure near‑term sentiment. FDA cites severe liver injury risk, unclear benefit behind Sanofi’s MS drug rejection
• Negative Sentiment: Reporting on regulatory rejection details (toxicities, unclear benefit) and trial shortcomings highlights development/investment risk and could prompt analysts to cut forecasts or delay approvals. Sanofi’s MS Drug Tripped Up By Toxicities, Unclear Benefit, Rejection Letter Reveals

Sanofi Trading Up 0.6%

The business’s fifty day simple moving average is €84.84 and its two-hundred day simple moving average is €83.82.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines.